Appendix Table 5.

Outcomes with colonoscopy screening strategies that vary by the ages to begin and end screening among transplant Cystic Fibrosis patients.

	Outcomes per 1,000 transplant cystic fibrosis individuals free of diagnosed cancer at age 30 years in 2017 (with organ transplant at age 30, 3% discounted)
	Screening tests		Surveillance COLs	Total COLs	Compli -cations	CRC Casesc	CRC deatha,c	LY with CRC	LYGb	Total costs (*$1,000)	Net costs (*$1,000)	Reductionsb (%)		Efficient strategy
	FIT	COLs										CRC incidencec	CRC mortalityc
No screening	0	0	0	30	0	52	22	115	0	2064654	0	0	0	Dominated
COL 50–55 y
3 y	0	125	173	314	2	48	13	143	15	2437339	372685	8	40	Dominated
5 y	0	125	152	293	1	48	14	143	14	2420864	356209	8	39	Dominated
10 y	0	124	151	293	1	48	14	143	14	2419742	355087	8	39	Dominated
COL 50–60 y
3 y	0	125	173	314	2	48	13	143	15	2437341	372687	8	40	Dominated
5 y	0	125	152	293	1	48	14	143	14	2420865	356211	8	39	Dominated
10 y	0	124	151	293	1	48	14	143	14	2420644	355990	8	39	Dominated
COL 50–65 y
3 y	0	125	173	314	2	48	13	143	15	2437341	372687	8	40	Dominated
5 y	0	125	152	293	1	48	14	143	14	2420865	356211	8	39	Dominated
10 y	0	124	151	293	1	48	14	143	14	2420644	355990	8	39	Dominated
COL 50–70 y
3 y	0	125	173	314	2	48	13	143	15	2437341	372687	8	40	Dominated
5 y	0	125	152	293	1	48	14	143	14	2420865	356211	8	39	Dominated
10 y	0	124	151	293	1	48	14	143	14	2420644	355990	8	39	Dominated
COL 50–75 y
3 y	0	125	173	314	2	48	13	143	15	2437341	372687	8	40	Dominated
5 y	0	125	152	293	1	48	14	143	14	2420865	356211	8	39	Dominated
10 y	0	124	151	293	1	48	14	143	14	2420644	355990	8	39	Dominated
COL 45–55 y
3 y	0	200	416	628	3	38	9	137	29	2481276	416622	27	59	Dominated
5 y	0	200	343	554	2	39	9	139	28	2438899	374244	25	58	Efficient
10 y	0	199	342	553	2	39	9	139	28	2438362	373707	25	57	Efficient
COL 45–60 y
3 y	0	200	416	628	3	38	9	137	29	2481280	416625	27	59	Dominated
5 y	0	200	343	554	2	39	9	139	28	2438902	374247	25	58	Dominated
10 y	0	199	342	553	2	39	9	139	28	2438362	373707	25	57	Dominated
COL 45–65 y
3 y	0	200	416	628	3	38	9	137	29	2481280	416625	27	59	Dominated
5 y	0	200	343	554	2	39	9	139	28	2438902	374247	25	58	Dominated
10 y	0	199	342	553	2	39	9	139	28	2438362	373707	25	57	Dominated
COL 45–70 y
3 y	0	200	416	628	3	38	9	137	29	2481280	416625	27	59	Dominated
5 y	0	200	343	554	2	39	9	139	28	2438902	374247	25	58	Dominated
10 y	0	199	342	553	2	39	9	139	28	2438362	373707	25	57	Dominated
COL 45–75 y
3 y	0	200	416	628	3	38	9	137	29	2481280	416625	27	59	Dominated
5 y	0	200	343	554	2	39	9	139	28	2438902	374247	25	58	Dominated
10 y	0	199	342	553	2	39	9	139	28	2438362	373707	25	57	Dominated
COL 40–55 y
3 y	0	328	774	1109	3	30	6	123	44	2707578	642923	42	74	Dominated
5 y	0	324	591	923	3	34	7	129	42	2600975	536321	36	70	Efficient
10 y	0	320	582	909	3	34	7	129	42	2597514	532860	35	70	Dominated
COL 40–60 y
3 y	0	328	774	1109	3	30	6	123	44	2707578	642924	42	74	Dominated
5 y	0	324	591	923	3	34	7	129	42	2600975	536321	36	70	Dominated
10 y	0	320	582	909	3	34	7	129	42	2597584	532929	35	70	Dominated
COL 40–65 y
3 y	0	328	774	1109	3	30	6	123	44	2707578	642924	42	74	Dominated
5 y	0	324	591	923	3	34	7	129	42	2600975	536321	36	70	Dominated
10 y	0	320	582	909	3	34	7	129	42	2597584	532929	35	70	Dominated
COL 40–70 y
3 y	0	328	774	1109	3	30	6	123	44	2707578	642924	42	74	Dominated
5 y	0	324	591	923	3	34	7	129	42	2600975	536321	36	70	Dominated
10 y	0	320	582	909	3	34	7	129	42	2597584	532929	35	70	Dominated
COL 40–75 y
3 y	0	328	774	1109	3	30	6	123	44	2707578	642924	42	74	Dominated
5 y	0	324	591	923	3	34	7	129	42	2600975	536321	36	70	Dominated
10 y	0	320	582	909	3	34	7	129	42	2597584	532929	35	70	Dominated
COL 35–55 y
3 y	0	642	1265	1912	4	26	4	110	56	3346546	1281892	49	82	Optimal
5 y	0	607	838	1451	3	31	5	122	52	3028100	963446	41	77	Efficient
10 y	0	571	788	1364	3	32	6	125	49	2980739	916084	39	75	Dominated
COL 35–60 y
3 y	0	642	1265	1912	4	26	4	110	56	3346548	1281894	49	82	Dominated
5 y	0	607	838	1451	3	31	5	122	52	3028100	963446	41	77	Dominated
10 y	0	571	788	1364	3	32	6	125	49	2980739	916084	39	75	Dominated
COL 35–65 y
3 y	0	642	1265	1912	4	26	4	110	56	3346548	1281894	49	82	Dominated
5 y	0	607	838	1451	3	31	5	122	52	3028100	963446	41	77	Dominated
10 y	0	571	788	1364	3	32	6	125	49	2980739	916084	39	75	Dominated
COL 35–70 y
3 y	0	642	1265	1912	4	26	4	110	56	3346548	1281894	49	82	Dominated
5 y	0	607	838	1451	3	31	5	122	52	3028100	963446	41	77	Dominated
10 y	0	571	788	1364	3	32	6	125	49	2980739	916084	39	75	Dominated
COL 35–75 y
3 y	0	642	1265	1912	4	26	4	110	56	3346548	1281894	49	82	Dominated
5 y	0	607	838	1451	3	31	5	122	52	3028100	963446	41	77	Dominated
10 y	0	571	788	1364	3	32	6	125	49	2980739	916084	39	75	Dominated
COL 30–55 y
3 y	0	1511	1826	3340	5	25	3	99	64	4622190	2557535	53	87	Efficient
5 y	0	1316	1080	2400	4	29	4	117	57	3888961	1824306	43	80	Dominated
10 y	0	1134	971	2110	4	31	5	121	54	3656737	1592083	41	77	Dominated
COL 30–60 y
3 y	0	1511	1826	3340	5	25	3	99	64	4622193	2557539	53	87	Dominated
5 y	0	1316	1080	2400	4	29	4	117	57	3888964	1824309	43	80	Dominated
10 y	0	1134	971	2110	4	31	5	121	54	3656827	1592172	41	78	Dominated
COL 30–65 y
3 y	0	1511	1826	3340	5	25	3	99	64	4622193	2557539	53	87	Dominated
5 y	0	1316	1080	2400	4	29	4	117	57	3888964	1824309	43	80	Dominated
10 y	0	1134	971	2110	4	31	5	121	54	3656827	1592172	41	78	Dominated
COL 30–70 y
3 y	0	1511	1826	3340	5	25	3	99	64	4622193	2557539	53	87	Dominated
5 y	0	1316	1080	2400	4	29	4	117	57	3888964	1824309	43	80	Dominated
10 y	0	1134	971	2110	4	31	5	121	54	3656827	1592172	41	78	Dominated
COL 30–75 y
3 y	0	1511	1826	3340	5	25	3	99	64	4622193	2557539	53	87	Dominated
5 y	0	1316	1080	2400	4	29	4	117	57	3888964	1824309	43	80	Dominated
10 y	0	1134	971	2110	4	31	5	121	54	3656827	1592172	41	78	Dominated

COL indicates colonoscopy; CRC, colorectal cancer; LY, Life-years; LYG, LY gained compared with no screening; Grey row indicates optimal screening strategy.

^aIncluding deaths from complications of screening;

^bcompared with no screening;

^cCRC cases and CRC death were not discounted.